NSIP LLC is the General Partner of Ellington Healthcare Partners I, L.P. a venture capital investment fund that targets companies with unique therapies using adult stem cells which typically are bone-marrow derived, nanotechnology devices, or molecular targeted, oncologic pharmaceuticals that clearly demonstrate potential breakthroughs in the treatment of disease or possess competitive advantages over currently-marketed products.